The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.

The Biosimilars Operational Readiness group is an initiative focused on developing resources to aid in the assessment and implementation of biosimilars when formulary coverage is approved. This group will launch in Q4 2022.

Today, the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) announced that it has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review.

Sponsored webinar that reviews biosimilar substitution strategies employed by health plans and employer groups within Michigan.

Where We Stand: The Academy of Managed Care Pharmacy (AMCP) supports an abbreviated licensure pathway for the approval of biosimilar biologic drug therapies.

AMCP applauds the FDA approval of the first interchangeable biosimilar insulin product.

AMCP webinar that reviewed proceedings from this Partnership Forum.